+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Myeloproliferative Disorders Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • PDF Icon

    Report

  • 100 Pages
  • May 2025
  • Region: Global
  • Prof Research
  • ID: 6090503
Description Jump to:
Myeloproliferative disorders (MPD) drugs, including JAK inhibitors, tyrosine kinase inhibitors (TKIs), interferons, and others, treat conditions like chronic myelogenous leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis, with 20,000 new U.S. cases annually. The market is driven by an aging population (1 billion over 60 in 2020, projected to reach 2.1 billion by 2050), with PV and ET incidence at 2-3 per 100,000 in those over 65. Novel therapies like ruxolitinib (90% JAK2 mutation detection in PV) and FDA approvals, such as asciminib for CML in 2024, boost growth. Precision medicine improves efficacy by 30%. The global MPD drugs market is estimated at USD 6.0-11.0 billion in 2025, with a CAGR of 3%-8% through 2030.

Regional Market Trends

  • North America: The U.S. leads with high MPD prevalence and novel therapy adoption, while Canada emphasizes targeted treatments.
  • Europe: Germany, France, and the UK drive growth with advanced hematology care.
  • Asia Pacific: Japan and China see rising cases due to aging, with India focusing on generics.
  • Rest of the World: Brazil enhances oncology infrastructure, while the Middle East addresses rare diseases.

Application Analysis

  • Hospitals: Expected growth of 3.5%-8.5%, driven by acute MPD cases. Trends focus on specialized oncology units.
  • Specialty Clinics: Projected growth of 3.2%-8.2%, linked to chronic management. Advances emphasize outpatient care.
  • Others: Anticipated growth of 3.0%-8.0%, covering home care. Trends highlight patient support programs.

Type Analysis

  • JAK Inhibitors: Expected growth of 4.0%-9.0%, effective for myelofibrosis. Trends focus on ruxolitinib and fedratinib.
  • TKIs: Projected growth of 3.8%-8.8%, for CML treatment. Advances emphasize asciminib and imatinib generics.
  • IFNs: Anticipated growth of 3.5%-8.5%, used in PV and ET. Trends highlight long-acting formulations.
  • Others: Expected growth of 3.2%-8.2%, covering emerging therapies. Developments prioritize precision medicine.

Key Market Players

  • Novartis: Offers asciminib and imatinib for CML.
  • Bristol-Myers Squibb: Develops TKIs for MPD treatment.
  • Pfizer: Provides supportive MPD therapies.
  • Incyte: Pioneers ruxolitinib for myelofibrosis.
  • GSK: Supplies momelotinib for myelofibrosis.

Porter’s Five Forces Analysis

  • Threat of New Entrants: Low, due to high R&D costs and orphan drug regulations.
  • Threat of Substitutes: Low, as targeted therapies are essential, with few alternatives.
  • Bargaining Power of Buyers: Moderate, as insurers negotiate prices, but limited options strengthen providers.
  • Bargaining Power of Suppliers: Low, with multiple suppliers of active ingredients.
  • Competitive Rivalry: High, with companies competing on efficacy, safety, and speed to market.

Market Opportunities and Challenges

Opportunities:

  • Addressing 20,000 new U.S. MPD cases annually.
  • Targeting an aging population, with 2-3/100,000 PV and ET incidence.
  • Leveraging JAK inhibitors, with 90% JAK2 mutation detection.
  • Utilizing precision medicine, improving efficacy by 30%.
  • Benefiting from FDA orphan drug approvals.
  • Expanding targeted therapies for rare MPDs.

Challenges:

  • High costs of novel therapies limiting access.
  • Regulatory delays for pipeline drugs.
  • Limited MPD awareness in developing regions.
  • Side effects of JAK inhibitors requiring monitoring.
  • Competition from supportive care options.

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1 Executive SummaryChapter 2 Abbreviation and Acronyms
Chapter 3 Preface
3.1 Research Scope
3.2 Research Sources
3.2.1 Data Sources
3.2.2 Assumptions
3.3 Research Method
Chapter 4 Market Landscape
4.1 Market Overview
4.2 Classification/Types
4.3 Application/End Users
Chapter 5 Market Trend Analysis
5.1 Introduction
5.2 Drivers
5.3 Restraints
5.4 Opportunities
5.5 Threats
Chapter 6 Industry Chain Analysis
6.1 Upstream/Suppliers Analysis
6.2 Myeloproliferative Disorders Drug Analysis
6.2.1 Technology Analysis
6.2.2 Cost Analysis
6.2.3 Market Channel Analysis
6.3 Downstream Buyers/End Users
Chapter 7 Latest Market Dynamics
7.1 Latest News
7.2 Merger and Acquisition
7.3 Planned/Future Project
7.4 Policy Dynamics
Chapter 8 Historical and Forecast Myeloproliferative Disorders Drug Market in North America (2020-2030)
8.1 Myeloproliferative Disorders Drug Market Size
8.2 Myeloproliferative Disorders Drug Market by End Use
8.3 Competition by Players/Suppliers
8.4 Myeloproliferative Disorders Drug Market Size by Type
8.5 Key Countries Analysis
8.5.1 United States
8.5.2 Canada
8.5.3 Mexico
Chapter 9 Historical and Forecast Myeloproliferative Disorders Drug Market in South America (2020-2030)
9.1 Myeloproliferative Disorders Drug Market Size
9.2 Myeloproliferative Disorders Drug Market by End Use
9.3 Competition by Players/Suppliers
9.4 Myeloproliferative Disorders Drug Market Size by Type
9.5 Key Countries Analysis
9.5.1 Brazil
9.5.2 Argentina
9.5.3 Chile
9.5.4 Peru
Chapter 10 Historical and Forecast Myeloproliferative Disorders Drug Market in Asia & Pacific (2020-2030)
10.1 Myeloproliferative Disorders Drug Market Size
10.2 Myeloproliferative Disorders Drug Market by End Use
10.3 Competition by Players/Suppliers
10.4 Myeloproliferative Disorders Drug Market Size by Type
10.5 Key Countries Analysis
10.5.1 China
10.5.2 India
10.5.3 Japan
10.5.4 South Korea
10.5.5 Southeast Asia
10.5.6 Australia
Chapter 11 Historical and Forecast Myeloproliferative Disorders Drug Market in Europe (2020-2030)
11.1 Myeloproliferative Disorders Drug Market Size
11.2 Myeloproliferative Disorders Drug Market by End Use
11.3 Competition by Players/Suppliers
11.4 Myeloproliferative Disorders Drug Market Size by Type
11.5 Key Countries Analysis
11.5.1 Germany
11.5.2 France
11.5.3 United Kingdom
11.5.4 Italy
11.5.5 Spain
11.5.6 Belgium
11.5.7 Netherlands
11.5.8 Austria
11.5.9 Poland
11.5.10 Russia
Chapter 12 Historical and Forecast Myeloproliferative Disorders Drug Market in MEA (2020-2030)
12.1 Myeloproliferative Disorders Drug Market Size
12.2 Myeloproliferative Disorders Drug Market by End Use
12.3 Competition by Players/Suppliers
12.4 Myeloproliferative Disorders Drug Market Size by Type
12.5 Key Countries Analysis
12.5.1 Egypt
12.5.2 Israel
12.5.3 South Africa
12.5.4 Gulf Cooperation Council Countries
12.5.5 Turkey
Chapter 13 Summary For Global Myeloproliferative Disorders Drug Market (2020-2025)
13.1 Myeloproliferative Disorders Drug Market Size
13.2 Myeloproliferative Disorders Drug Market by End Use
13.3 Competition by Players/Suppliers
13.4 Myeloproliferative Disorders Drug Market Size by Type
Chapter 14 Global Myeloproliferative Disorders Drug Market Forecast (2025-2030)
14.1 Myeloproliferative Disorders Drug Market Size Forecast
14.2 Myeloproliferative Disorders Drug Application Forecast
14.3 Competition by Players/Suppliers
14.4 Myeloproliferative Disorders Drug Type Forecast
Chapter 15 Analysis of Global Key Vendors
15.1 Novartis
15.1.1 Company Profile
15.1.2 Main Business and Myeloproliferative Disorders Drug Information
15.1.3 SWOT Analysis of Novartis
15.1.4 Novartis Myeloproliferative Disorders Drug Revenue, Gross Margin and Market Share (2020-2025)
15.2 Bristol-Myers Squibb
15.2.1 Company Profile
15.2.2 Main Business and Myeloproliferative Disorders Drug Information
15.2.3 SWOT Analysis of Bristol-Myers Squibb
15.2.4 Bristol-Myers Squibb Myeloproliferative Disorders Drug Revenue, Gross Margin and Market Share (2020-2025)
15.3 Pfizer
15.3.1 Company Profile
15.3.2 Main Business and Myeloproliferative Disorders Drug Information
15.3.3 SWOT Analysis of Pfizer
15.3.4 Pfizer Myeloproliferative Disorders Drug Revenue, Gross Margin and Market Share (2020-2025)
15.4 Incyte
15.4.1 Company Profile
15.4.2 Main Business and Myeloproliferative Disorders Drug Information
15.4.3 SWOT Analysis of Incyte
15.4.4 Incyte Myeloproliferative Disorders Drug Revenue, Gross Margin and Market Share (2020-2025)
15.5 GSK
15.5.1 Company Profile
15.5.2 Main Business and Myeloproliferative Disorders Drug Information
15.5.3 SWOT Analysis of GSK
15.5.4 GSK Myeloproliferative Disorders Drug Revenue, Gross Margin and Market Share (2020-2025)
15.6 Eli Lilly
15.6.1 Company Profile
15.6.2 Main Business and Myeloproliferative Disorders Drug Information
15.6.3 SWOT Analysis of Eli Lilly
15.6.4 Eli Lilly Myeloproliferative Disorders Drug Revenue, Gross Margin and Market Share (2020-2025)
15.7 Takeda Pharmaceutical
15.7.1 Company Profile
15.7.2 Main Business and Myeloproliferative Disorders Drug Information
15.7.3 SWOT Analysis of Takeda Pharmaceutical
15.7.4 Takeda Pharmaceutical Myeloproliferative Disorders Drug Revenue, Gross Margin and Market Share (2020-2025)
15.8 Teva Pharmaceutical
15.8.1 Company Profile
15.8.2 Main Business and Myeloproliferative Disorders Drug Information
15.8.3 SWOT Analysis of Teva Pharmaceutical
15.8.4 Teva Pharmaceutical Myeloproliferative Disorders Drug Revenue, Gross Margin and Market Share (2020-2025)
15.9 AbbVie
15.9.1 Company Profile
15.9.2 Main Business and Myeloproliferative Disorders Drug Information
15.9.3 SWOT Analysis of AbbVie
15.9.4 AbbVie Myeloproliferative Disorders Drug Revenue, Gross Margin and Market Share (2020-2025)
15.10 GL Pharma
15.10.1 Company Profile
15.10.2 Main Business and Myeloproliferative Disorders Drug Information
15.10.3 SWOT Analysis of GL Pharma
15.10.4 GL Pharma Myeloproliferative Disorders Drug Revenue, Gross Margin and Market Share (2020-2025)
15.11 Hikma Pharmaceuticals
15.11.1 Company Profile
15.11.2 Main Business and Myeloproliferative Disorders Drug Information
15.11.3 SWOT Analysis of Hikma Pharmaceuticals
15.11.4 Hikma Pharmaceuticals Myeloproliferative Disorders Drug Revenue, Gross Margin and Market Share (2020-2025)
15.12 Sun Pharmaceutical
15.12.1 Company Profile
15.12.2 Main Business and Myeloproliferative Disorders Drug Information
15.12.3 SWOT Analysis of Sun Pharmaceutical
15.12.4 Sun Pharmaceutical Myeloproliferative Disorders Drug Revenue, Gross Margin and Market Share (2020-2025)
15.13 Apotex
15.13.1 Company Profile
15.13.2 Main Business and Myeloproliferative Disorders Drug Information
15.13.3 SWOT Analysis of Apotex
15.13.4 Apotex Myeloproliferative Disorders Drug Revenue, Gross Margin and Market Share (2020-2025)
15.14 AOP Health Group
15.14.1 Company Profile
15.14.2 Main Business and Myeloproliferative Disorders Drug Information
15.14.3 SWOT Analysis of AOP Health Group
15.14.4 AOP Health Group Myeloproliferative Disorders Drug Revenue, Gross Margin and Market Share (2020-2025)
List of Tables and Figures
Table Abbreviation and Acronyms
Table Research Scope of Myeloproliferative Disorders Drug Report
Table Data Sources of Myeloproliferative Disorders Drug Report
Table Major Assumptions of Myeloproliferative Disorders Drug Report
Figure Market Size Estimated Method
Figure Major Forecasting Factors
Figure Myeloproliferative Disorders Drug Picture
Table Myeloproliferative Disorders Drug Classification
Table Myeloproliferative Disorders Drug Applications
Table Drivers of Myeloproliferative Disorders Drug Market
Table Restraints of Myeloproliferative Disorders Drug Market
Table Opportunities of Myeloproliferative Disorders Drug Market
Table Threats of Myeloproliferative Disorders Drug Market
Table COVID-19 Impact For Myeloproliferative Disorders Drug Market
Table Raw Materials Suppliers
Table Different Production Methods of Myeloproliferative Disorders Drug
Table Cost Structure Analysis of Myeloproliferative Disorders Drug
Table Key End Users
Table Latest News of Myeloproliferative Disorders Drug Market
Table Merger and Acquisition
Table Planned/Future Project of Myeloproliferative Disorders Drug Market
Table Policy of Myeloproliferative Disorders Drug Market
Table 2020-2030 North America Myeloproliferative Disorders Drug Market Size
Figure 2020-2030 North America Myeloproliferative Disorders Drug Market Size and CAGR
Table 2020-2030 North America Myeloproliferative Disorders Drug Market Size by Application
Table 2020-2025 North America Myeloproliferative Disorders Drug Key Players Revenue
Table 2020-2025 North America Myeloproliferative Disorders Drug Key Players Market Share
Table 2020-2030 North America Myeloproliferative Disorders Drug Market Size by Type
Table 2020-2030 United States Myeloproliferative Disorders Drug Market Size
Table 2020-2030 Canada Myeloproliferative Disorders Drug Market Size
Table 2020-2030 Mexico Myeloproliferative Disorders Drug Market Size
Table 2020-2030 South America Myeloproliferative Disorders Drug Market Size
Figure 2020-2030 South America Myeloproliferative Disorders Drug Market Size and CAGR
Table 2020-2030 South America Myeloproliferative Disorders Drug Market Size by Application
Table 2020-2025 South America Myeloproliferative Disorders Drug Key Players Revenue
Table 2020-2025 South America Myeloproliferative Disorders Drug Key Players Market Share
Table 2020-2030 South America Myeloproliferative Disorders Drug Market Size by Type
Table 2020-2030 Brazil Myeloproliferative Disorders Drug Market Size
Table 2020-2030 Argentina Myeloproliferative Disorders Drug Market Size
Table 2020-2030 Chile Myeloproliferative Disorders Drug Market Size
Table 2020-2030 Peru Myeloproliferative Disorders Drug Market Size
Table 2020-2030 Asia & Pacific Myeloproliferative Disorders Drug Market Size
Figure 2020-2030 Asia & Pacific Myeloproliferative Disorders Drug Market Size and CAGR
Table 2020-2030 Asia & Pacific Myeloproliferative Disorders Drug Market Size by Application
Table 2020-2025 Asia & Pacific Myeloproliferative Disorders Drug Key Players Revenue
Table 2020-2025 Asia & Pacific Myeloproliferative Disorders Drug Key Players Market Share
Table 2020-2030 Asia & Pacific Myeloproliferative Disorders Drug Market Size by Type
Table 2020-2030 China Myeloproliferative Disorders Drug Market Size
Table 2020-2030 India Myeloproliferative Disorders Drug Market Size
Table 2020-2030 Japan Myeloproliferative Disorders Drug Market Size
Table 2020-2030 South Korea Myeloproliferative Disorders Drug Market Size
Table 2020-2030 Southeast Asia Myeloproliferative Disorders Drug Market Size
Table 2020-2030 Australia Myeloproliferative Disorders Drug Market Size
Table 2020-2030 Europe Myeloproliferative Disorders Drug Market Size
Figure 2020-2030 Europe Myeloproliferative Disorders Drug Market Size and CAGR
Table 2020-2030 Europe Myeloproliferative Disorders Drug Market Size by Application
Table 2020-2025 Europe Myeloproliferative Disorders Drug Key Players Revenue
Table 2020-2025 Europe Myeloproliferative Disorders Drug Key Players Market Share
Table 2020-2030 Europe Myeloproliferative Disorders Drug Market Size by Type
Table 2020-2030 Germany Myeloproliferative Disorders Drug Market Size
Table 2020-2030 France Myeloproliferative Disorders Drug Market Size
Table 2020-2030 United Kingdom Myeloproliferative Disorders Drug Market Size
Table 2020-2030 Italy Myeloproliferative Disorders Drug Market Size
Table 2020-2030 Spain Myeloproliferative Disorders Drug Market Size
Table 2020-2030 Belgium Myeloproliferative Disorders Drug Market Size
Table 2020-2030 Netherlands Myeloproliferative Disorders Drug Market Size
Table 2020-2030 Austria Myeloproliferative Disorders Drug Market Size
Table 2020-2030 Poland Myeloproliferative Disorders Drug Market Size
Table 2020-2030 Russia Myeloproliferative Disorders Drug Market Size
Table 2020-2030 MEA Myeloproliferative Disorders Drug Market Size
Figure 2020-2030 MEA Myeloproliferative Disorders Drug Market Size and CAGR
Table 2020-2030 MEA Myeloproliferative Disorders Drug Market Size by Application
Table 2020-2025 MEA Myeloproliferative Disorders Drug Key Players Revenue
Table 2020-2025 MEA Myeloproliferative Disorders Drug Key Players Market Share
Table 2020-2030 MEA Myeloproliferative Disorders Drug Market Size by Type
Table 2020-2030 Egypt Myeloproliferative Disorders Drug Market Size
Table 2020-2030 Israel Myeloproliferative Disorders Drug Market Size
Table 2020-2030 South Africa Myeloproliferative Disorders Drug Market Size
Table 2020-2030 Gulf Cooperation Council Countries Myeloproliferative Disorders Drug Market Size
Table 2020-2030 Turkey Myeloproliferative Disorders Drug Market Size
Table 2020-2025 Global Myeloproliferative Disorders Drug Market Size by Region
Table 2020-2025 Global Myeloproliferative Disorders Drug Market Size Share by Region
Table 2020-2025 Global Myeloproliferative Disorders Drug Market Size by Application
Table 2020-2025 Global Myeloproliferative Disorders Drug Market Share by Application
Table 2020-2025 Global Myeloproliferative Disorders Drug Key Vendors Revenue
Figure 2020-2025 Global Myeloproliferative Disorders Drug Market Size and Growth Rate
Table 2020-2025 Global Myeloproliferative Disorders Drug Key Vendors Market Share
Table 2020-2025 Global Myeloproliferative Disorders Drug Market Size by Type
Table 2020-2025 Global Myeloproliferative Disorders Drug Market Share by Type
Table 2025-2030 Global Myeloproliferative Disorders Drug Market Size by Region
Table 2025-2030 Global Myeloproliferative Disorders Drug Market Size Share by Region
Table 2025-2030 Global Myeloproliferative Disorders Drug Market Size by Application
Table 2025-2030 Global Myeloproliferative Disorders Drug Market Share by Application
Table 2025-2030 Global Myeloproliferative Disorders Drug Key Vendors Revenue
Figure 2025-2030 Global Myeloproliferative Disorders Drug Market Size and Growth Rate
Table 2025-2030 Global Myeloproliferative Disorders Drug Key Vendors Market Share
Table 2025-2030 Global Myeloproliferative Disorders Drug Market Size by Type
Table 2025-2030 Myeloproliferative Disorders Drug Global Market Share by Type

Companies Mentioned

  • Novartis
  • Bristol-Myers Squibb
  • Pfizer
  • Incyte
  • GSK
  • Eli Lilly
  • Takeda Pharmaceutical
  • Teva Pharmaceutical
  • AbbVie
  • GL Pharma
  • Hikma Pharmaceuticals
  • Sun Pharmaceutical
  • Apotex
  • AOP Health Group

Related Topics

Related Reports

Myeloproliferative Disorders Drugs - Global Strategic Business Report - Product Image

Myeloproliferative Disorders Drugs - Global Strategic Business Report

  • Report
  • 172 Pages
  • Global
From
Myeloproliferative Disorders Drugs Market Report 2025 - Product Image

Myeloproliferative Disorders Drugs Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Myeloproliferative Disorders Drugs Market Size, Share & Trends Analysis Report By Indication, By Treatment Type, By End Use, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Myeloproliferative Disorders Drugs Market Size, Share & Trends Analysis Report By Indication, By Treatment Type, By End Use, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Myeloproliferative Neoplasms Treatment - Global Strategic Business Report - Product Image

Myeloproliferative Neoplasms Treatment - Global Strategic Business Report

  • Report
  • 368 Pages
  • Global
From
Myeloproliferative Neoplasms - Pipeline Insight, 2025 - Product Image

Myeloproliferative Neoplasms - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.